Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Shanavas M, et al. Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19. Biol Blood Marrow Transplant. 2016. PMID: 26493563 Free PMC article. Clinical Trial.
A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. Shanavas M, et al. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92. doi: 10.1016/j.clml.2013.09.010. Epub 2013 Oct 1. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24252361
Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Uhm J, Hamad N, Shin EM, Michelis FV, Shanavas M, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Seftel M, Kim DD. Uhm J, et al. Among authors: shanavas m. Biol Blood Marrow Transplant. 2014 Nov;20(11):1751-7. doi: 10.1016/j.bbmt.2014.07.001. Epub 2014 Jul 17. Biol Blood Marrow Transplant. 2014. PMID: 25042736 Free article.
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
Uhm J, Hamad N, Michelis FV, Shanavas M, Kuruvilla J, Gupta V, Lipton JH, Messner HA, Seftel M, Kim DD. Uhm J, et al. Among authors: shanavas m. Bone Marrow Transplant. 2014 Dec;49(12):1528-34. doi: 10.1038/bmt.2014.181. Epub 2014 Aug 11. Bone Marrow Transplant. 2014. PMID: 25111517
Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. Shanavas M, et al. Leuk Lymphoma. 2014 Oct;55(10):2398-401. doi: 10.3109/10428194.2014.882507. Epub 2014 Mar 7. Leuk Lymphoma. 2014. PMID: 24428200 No abstract available.
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. Cappellini MD, et al. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. N Engl J Med. 2020. PMID: 32212518 Clinical Trial.
25 results